Loading...

Neuronetics, Inc.

STIMNASDAQ
Healthcare
Medical - Diagnostics & Research
$3.27
$-0.10(-3.11%)

Neuronetics, Inc. (STIM) Financial Performance & Income Statement Overview

Access detailed quarterly and annual financial reports for Neuronetics, Inc. (STIM), covering cash flow, earnings, and balance sheets.

Revenue Growth
4.96%
4.96%
Operating Income Growth
-13.12%
13.12%
Net Income Growth
-44.78%
44.78%
Operating Cash Flow Growth
3.25%
3.25%
Operating Margin
-34.45%
34.45%
Gross Margin
56.15%
56.15%
Net Profit Margin
-43.47%
43.47%
ROE
-193.78%
193.78%
ROIC
-35.82%
35.82%

Neuronetics, Inc. (STIM) Income Statement & Financial Overview

Access detailed annual and quarterly income data for Neuronetics, Inc. STIM financial performance.

MetricQ2 2025Q1 2025Q4 2024Q3 2024
Revenue$38.11M$31.98M$22.49M$18.53M
Cost of Revenue$20.35M$16.24M$7.60M$4.53M
Gross Profit$17.76M$15.74M$14.89M$14.001M
Gross Profit Ratio$0.47$0.49$0.66$0.76
R&D Expenses$1.80M$1.62M$5.77M$2.42M
SG&A Expenses$24.02M$25.14M$20.59M$19.31M
Operating Expenses$25.82M$26.75M$26.36M$21.73M
Total Costs & Expenses$46.17M$42.99M$33.96M$26.26M
Interest Income$0.00$0.00$0.00$0.00
Interest Expense$1.97M$1.92M$1.76M$1.73M
Depreciation & Amortization$0.00$911000.00$446000.00$512000.00
EBITDA-$8.06M-$9.86M-$10.48M-$11.10M
EBITDA Ratio-$0.21-$0.31-$0.47-$0.60
Operating Income-$8.06M-$11.01M-$11.47M-$7.73M
Operating Income Ratio-$0.21-$0.34-$0.51-$0.42
Other Income/Expenses (Net)-$2.06M-$1.68M-$1.22M-$5.61M
Income Before Tax-$10.12M-$12.69M-$12.70M-$13.34M
Income Before Tax Ratio-$0.27-$0.40-$0.56-$0.72
Income Tax Expense$0.00$0.00$0.00$0.00
Net Income-$10.12M-$12.68M-$12.16M-$13.34M
Net Income Ratio-$0.27-$0.40-$0.54-$0.72
EPS-$0.15-$0.21-$0.33-$0.44
Diluted EPS-$0.15-$0.21-$0.33-$0.44
Weighted Avg Shares Outstanding$66.18M$61.47M$36.67M$30.27M
Weighted Avg Shares Outstanding (Diluted)$66.18M$61.47M$36.67M$30.27M

Over the last four quarters, Neuronetics, Inc. achieved steady financial progress, growing revenue from $18.53M in Q3 2024 to $38.11M in Q2 2025. Gross profit stayed firm with margins at 47% in Q2 2025 versus 76% in Q3 2024. Operating income totaled -$8.06M in Q2 2025, maintaining a -21% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at -$8.06M. Net income rose to -$10.12M, with EPS at -$0.15. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;